Cancer clinical trials in the region Occitanie
404 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT06790693
#2024-516162-11-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
12 recruiting sites
Hoffmann-La Roche
Phase 3
Breast cancer
#NCT06492616
#2024-515445-42-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at localized stage
Hormone therapy
22 recruiting sites
Stemline Therapeutics, Inc.
Phase 3
Acute leukemia
#NCT06852222
#2024-520154-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
13 recruiting sites
Janssen
Phase 3
Acute leukemia
#NCT05907057
#2022-501709-11
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Chemotherapy
3 recruiting sites
Servier
Phase 3
Breast cancer
#NCT06435429
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Jazz Pharmaceuticals
Phase 3
Lung cancer
#NCT06345729
#2023-507776-42-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Prostate cancer
#NCT07213674
#2025-520555-89-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Amgen
Phase 3
Endometrial cancer
#NCT06712472
#2023-503886-44-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Required FIGO stages
Stage I
Stage II
Stage III
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
Excluded genetic anomalies
MSI/dMMR
POLE
14 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Prostate cancer
#NCT06952803
#2024-513586-39-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Biochemical recurrence
Required genetic anomalies
BRCA 1/2
Required previous treatments at localized stage
Radiotherapy
Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Targeted therapy
19 recruiting sites
AstraZeneca
Phase 3
Liver and bile duct cancer
#NCT06467357
#2023-508057-19-00
Required histologic sub types
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
8 recruiting sites
AstraZeneca